PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Paradigm patent rejection, page-37

  1. 75 Posts.
    lightbulb Created with Sketch. 77
    The US Patent Office "Final Rejection" of our most important patent is clearly material and demands an ASX announcement ASAP. It would be good to hear what Meltzer thinks. Our ship may have hit an iceberg. Damage control is essential.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.